Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Apyx Medical Corp (APYX)

Apyx Medical Corp (APYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates Zacks - Wed May 10, 2023

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -60% and 12.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BLFS : 17.95 (-0.44%)
APYX : 1.4150 (+0.35%)
ZimVie Inc. (ZIMV) Tops Q1 Earnings and Revenue Estimates Zacks - Wed May 3, 2023

ZimVie Inc. (ZIMV) delivered earnings and revenue surprises of 525% and 9.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ZIMV : 15.63 (-1.08%)
APYX : 1.4150 (+0.35%)
RENUVION® RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTION PR Newswire - Tue May 2, 2023

/PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX), the manufacturer of the proprietary helium plasma and radiofrequency technology marketed and sold as...

APYX : 1.4150 (+0.35%)
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring Business Wire - Fri Apr 28, 2023

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced it has received...

APYX : 1.4150 (+0.35%)
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023 Business Wire - Wed Apr 5, 2023

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial...

APYX : 1.4150 (+0.35%)
Renuvion Wins ADDY® Award for #ThisIsMe Campaign PR Newswire - Mon Mar 27, 2023

/PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX), the manufacturer of the proprietary helium plasma and radiofrequency technology marketed and sold as...

APYX : 1.4150 (+0.35%)
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Financial Outlook Business Wire - Thu Mar 16, 2023

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results...

APYX : 1.4150 (+0.35%)
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissue, Where Needed Business Wire - Mon Feb 27, 2023

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced it has received...

APYX : 1.4150 (+0.35%)
Apyx Medical Corporation Announces New Five-Year Credit Agreement with MidCap Financial Business Wire - Tue Feb 21, 2023

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that the Company...

APYX : 1.4150 (+0.35%)
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2022 Financial Results on March 16, 2023 Business Wire - Thu Feb 16, 2023

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial...

APYX : 1.4150 (+0.35%)

Barchart Exclusives

NVIDA Stock Is Still Undervalued, and Shorting Its Put Options Are Still are Great Income Play Barchart - 14 minutes ago
Nvidia stock still looks undervalued here, even though the stock keeps rising. This is based on higher analyst revenue and FCF estimates. This creates a good short-put play, especially for existing investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot